1.Content Determination of Asperosaponin Ⅵ in Yulin Mixture by HPLC
Lingling XU ; Yuxuan ZHANG ; Hua NIAN
China Pharmacy 2005;0(19):-
OBJECTIVE:To establish HPLC method for the content determination of asperosaponin Ⅵ in Yulin mixture.ME-THODS:The separation was performed on Zorbax EcLipse XDB-C18(150 mm?4.6 mm,5 ?m) column with mobile phase consisted of methanol-0.01 mol?L-1 hydrochloric acid (69:31) and flow rate of 1 mL?min-1.The detection wavelength was set at 212 nm and column temperature was 20 ℃.RESULTS:The linear range of asperosaponin Ⅵ was 0.022~0.23 mg?mL-1(r=0.998 9) with an average recovery of 101.33% (RSD=2.35%,n=9).CONCLUSION:The method is convenient,simple,accurate and reproducibility for the quality control of Yulin mixture.
2.Clinical study of chemotherapy combined with radiotherapy in the treatment of limited-stage small cell lung cancer
Nian-Chun CHEN ; Li-Hua ZHOU ; Wei-Ming ZHANG ;
Cancer Research and Clinic 2006;0(12):-
Objective To evaluate the curative effect of chemotherapy combined with radiotherapy for limited-stage small cell lung cancer(LD-SCLC).Methods 34 cases of patients with LD-SCLC were rand- mized into interdigitating chemoradiotherapy group and sequential chemoradiotherapy group.All patients re- ceived four to six cycles of alternating CE(C:carboplatin 300 mg/m~2 d_1;E:etoposide100 mg d_(1~5)and CAP(C: cyclophosphamide 600 mg/m~2 d_(1,8);A:adriamycin 40 mg/m~2 d_1;P:cisplatin 50 mg d_(3~5)chemotherapy,three weeks for a cycle.All patients also received thoracic radiotherapy with conventional fraction,2.0 Gy per frac- tion,five fractions per week.The total dose was 60 Gy.Results In interdigitating chemoradiotherapy group, CR was 64.7%,PR was 29.4%,NR was 5.9% and PD was 0 after chemo-radiation therapy.In sequential chemoradiotherapy group,CR was 23.5%,PR was 52.9%,NR was 23.5% and PD was 0 after chemothera- py,and CR was 58.8%,PR was 35.3%,NR was 5.9% and PD was 0 after radiotherapy.Conclusion The therapeutic effect of chemotherapy combined with radiotherapy for LD-SCLC was satisying.There was no sig- nificant difference in the effect between the two groups.
3.Screening of HIV-1 neutralizing antibody mimotopes in slow progressor from phage display peptide library
Xiaoli ZHANG ; Xiaoxu HAN ; Di DAI ; Mingjia BAO ; Zining ZHANG ; Min ZHAO ; Hua NIAN ; Hong SHANG
Chinese Journal of Laboratory Medicine 2012;35(9):838-842
ObjectiveTo screen mimetic HIV-1 neutralizing epitopes from plasma with high level neutralizing antibody,and to provide useful information for further study of the interaction between antigen and antibody.MethodsIn order to gain neutralizing antibody recognized mimotopes, we detected neutralizing antibodieslevelsof 11HIV-1infectedslowprogressorsbyPBMC-basedneutralization assays.High-titer HIV-neutralizing antibodies from plasma of SPs was used as the ligand for biopanning by phage-displayed random peptide library.Positive phage clones was evaluated by ELISA,sequenced,and analyzed for homology to HIV-1 env by local BLAST to deduce the neutralizing peptide.ResultsTwenty-two clones were obtained consistent with requirement through three rounds biopanning.After comparison analysis,twelve clones include C8 were obtained as mimotopes of neutralizing antibody,C40 located in gp41Ⅱ cluster with the highest titer by inhibition ratio may be as neutralizing epitope.Conclusion By the use of IgG antibodies from SPs to screen the phage random polypeptide library,one can acquire multiple phage mimetic peptides of HIV related antigen epitope.(Chin J Lab Med,2012,35:838-842 )
4.Study Advances in Traditional Chinese Medicines Used in Diabetic Refractory Wounds
Jingting ZHANG ; Minfeng WU ; Minghua MA ; Quangang ZHU ; Fulun LI ; Hua NIAN
China Pharmacist 2015;18(12):2138-2140
Refractory wounds are the common complication of diabetes,and the therapeutic scheme and methods are paid more and more attention nowadays. The influence of traditional Chinese medicines on diabetic wound healing, such as promoting fibroblasts proliferation, enhancing granulation tissue formation, increasing the secretion of growth factors and reducing the wound scar, was re-viewed in the paper to provide scientific basis and reference for traditional Chinese medicines used in diabetic refractory wounds.
5.Prevention of bone loss by aqueous extract of Epimedii sagittatum in an ovariectomized rat model of osteoporosis.
Hua NIAN ; Lingling XU ; Minghua MA ; Luping QIN ; Hanchen ZHENG ; Qiaoyan ZHANG
Journal of Integrative Medicine 2006;4(6):628-33
OBJECTIVE: To investigate the prevention effect of aqueous extract of Epimedii sagittatum (ESE) on ovariectomy-induced (OVX) bone loss in rats. METHODS: Rats were divided into sham-operated and OVX groups. The OVX rats were divided into four groups treated with distilled water, 17beta-estradiol (1 mg/kg, ig) and ESE (0.5 and 1 g/kg, ig) for 11 weeks. Serum calcium, phosphorus, estradiol, bone gla protein concentrations and serum alkaline phosphatase activity were measured. Bone density was assayed by dual-energy X-ray absorptiometry. The undecalcified longitudinal proximal tibial metaphysical sections were cut and stained for the bone histomorphometric analysis. RESULTS: In OVX rats, alkaline phosphatase activity in serum was markedly increased by ESE treatment, which had no obvious influence on the body weight. Meanwhile, atrophy of uterus and descent of bone mineral density were suppressed by ESE treatment. In addition, ESE completely corrected the decreased concentrations of calcium and E2 in serum observed in OVX rats. Histological results also showed ESE prevented the increases in trabecular separation (Tb.Sp) in OVX rats whereas it did not alter trabecular thickness (Tb.Th) and trabecular number (Tb.N) in OVX rats. Moreover, ESE had remarkable effect on bone formation rate with bone volume as referent (BFR/BV) and bone formation rate with bone surface as referent (BFR/BS). CONCLUSION: The findings assessed on the basis of biochemical test, bone mineral density and histomorphometric parameters show that aqueous extract of Epimedii sagittatum has a definite antiosteoporotic effect and can prevent the OVX-induced bone loss in rats.
6.Comment and Analysis for Prescriptions of Chinese Herbal Pieces in an Integrative Traditional Chinese and Western Medicine Hospital
Hua NIAN ; Minghua MA ; Yi XU ; Tiejun WU ; Jing LIU ; Jingting ZHANG ; Quangang ZHU
China Pharmacist 2016;19(2):319-321,322
Objective:To review and analyze the prescriptions for Chinese herbal pieces in an integrative traditional Chinese and western medicine hospital to explore the trend and problems in clinical application for Chinese herbal medicines and provide reference for dispensing in pharmacy of traditional medicine and rational drug use. Methods: Totally 1200 prescriptions for Chinese herbal pieces in our hospital were surveyed from January to December in 2014. The irrational use was analyzed, and reasonable suggestions were provided for the clinical application. Results:The problems in the prescriptions for Chinese herbal pieces included uncompleted diagnosis,incompatible diagnosis and medication,nonstandard Chinese name,unclear footnote,irrational usage or dosage and incompati-bility. The prescriptions including above 15 varieties of Chinese herbal pieces in one accounted for 65. 70%, and those with average dose above 250 g accounted for 40. 25%. Conclusion:Regular inspection and quality supervision on the prescription for Chinese herb-al pieces should be strengthened to improve the quality of prescriptions and guarantee the safety and economy of the medication.
7.Comparison of Efficacy and Safety of Docetaxel Combined with Carboplatin and Paclitaxel and Cisplatin in the Treatment of Advanced Ovarian Cancer
Yuanqiang HU ; Yongbo ZHANG ; Hua WANG ; Liyong ZHOU ; Gang XIONG ; Zekui CHEN ; Nian GUO ; Yue QIN
China Pharmacy 2016;27(24):3353-3355,3356
OBJECTIVE:To compare the efficacy,safety,vascular endothelial growth factor(VEGF)and matrix metallopro-teinase-2 (MMP-2) of docetaxel combined with carboplatin and paclitaxel combined with cisplatin (DDP) in the treatment of ad-vanced ovarian cancer. METHODS:120 patients with advanced ovarian cancer were randomly divided into docetaxel combined with carboplatin group(60 cases)and paclitaxel combined with DDP group(60 cases). Docetaxel combined with carboplatin group received 70 mg/m2 Docetaxel injection,intravenous infusion of 1 h,d1;50 mg/m2 carboplatin injection,intravenous infusion of 1 h,d2. Paclitaxel combined with DDP group received 135 mg/m2 Paclitaxel injection,intravenous infusion of 24 h,d1;30 mg/m2 DDP for injection,intravenous infusion,d3;60 mg/m2 Paclitaxel injection (a maximum of 2.0 m2) by intraperitoneal infusion,d8. 3-week was regarded as 1 treatment course,and it lasted 6 courses. Clinical efficacy,VEGF,MMP-2,progression-free survival, overall survival before and after treatment,mortality rate within 2 years of treatment and the incidence of adverse reactions in 2 groups were compared. RESULTS:There were no significant differences in the objective response rate,disease control rate,mortal-ity rate,incidence of adverse reactions between 2 groups(P>0.05). The progression-free survival in docetaxel combined with car-boplatin group was significantly longer than paclitaxel combined with DDP group,the difference was statistically significant (P<0.05). Before treatment,there were no significant differences in VEGF and MMP-2 level between 2 groups(P>0.05). After treat-ment,VEGF and MMP-2 level in 2 groups were significantly lower than before,and VEGF at different time points and MMP-2 level after 4 weeks,8 weeks and 12 weeks of treatment in docetaxel combined with carboplatin group were lower than paclitaxel combined with DDP group,the differences were statistically significant(P<0.05). CONCLUSIONS:Docetaxel combined with car-boplatin and paclitaxel combined with DDP shows similar efficacy and safety in the treatment of advanced ovarian cancer,but docetaxel carboplatin combined with is superior to paclitaxel combined with DDP in reducing VEGF and MMP-2 and improving pro-gression-free survival.
8.Littoral cell angioma of the spleen in a patient with chronic hepatitis B and hepatocellular carcinoma.
Chun-Nian WANG ; Xiang-Lei HE ; Hong-Bin ZHANG ; Hua-Xin DING
Chinese Journal of Pathology 2007;36(12):858-859
Carcinoma, Hepatocellular
;
complications
;
Hemangioma
;
complications
;
diagnosis
;
immunology
;
pathology
;
Hepatitis B, Chronic
;
complications
;
Hepatocytes
;
cytology
;
pathology
;
Humans
;
Liver Cirrhosis
;
complications
;
Liver Neoplasms
;
complications
;
Male
;
Middle Aged
;
Platelet Endothelial Cell Adhesion Molecule-1
;
immunology
;
Spleen
;
immunology
;
pathology
;
Tomography, X-Ray Computed
9.SLCO1B1 polymorphism associated with methotrexate disposition and clinical outcome
The Chinese Journal of Clinical Pharmacology 2014;(8):730-732
Organic anion transporting polypeptide 1B1 ( OATP1B1, en-coded by SLCO1B1 gene) plays a crucial role in the hepatic uptake of many endogenous compounds and xenobiotics.It has been demonstrated that SLCO1B1 polymorphism could change the pharmacokinetics charac-teristics of many clinically used drugs , which has influenced their out-come and safety.However , inter-individual variant of methotrexate re-sults in vastly different clinical effectiveness and toxicity.Herein, we re-view the current knowledge about this topic to provide theoretical guid-ance for the clinical use of methotrexate.
10.Study on the relationship between the expression of TLR7/8 in monocytes and the disease progression of HIV-1 infection
Hua NIAN ; Wenqing GENG ; Hualu CUI ; Zining ZHANG ; Min ZHANG ; Xiaoxu HAN ; Bin ZHAO ; Qinghai HU ; Hong SHANG
Chinese Journal of Microbiology and Immunology 2009;29(11):992-996
Objective To examine the expression of TLR7/8 in monocytes purified from HIV-1 infected individuals and to study its association with disease progression. Methods Sixty-three HIV-1 infected individuals and 18 normal controls were enrolled. Monocytes were purified by MACS system and RNA of them was extracted by RNA mini kit of QIAGEN company. TLR7/8 expression was tested by real-time RT-PCR with ABI7500. Results It was found that the expression of TLR7 was strongly correlated with absolute CD4 count (r =0.614, P<0.01) , so was TLR8 (r =0.419, P<0.01). The expression of TLR7 in slow progressor (SP) group was higher than that in HIV-1 infected patients group, AIDS patients group and normal group (P < 0. 05 ) . HIV group and normal group were strongly higher than AIDS group (P < 0. 05). It was no significant differentiation of expression of TLR7 between HIV infection group and normal control group. The expression of TLR8 in SP group and normal group were significantly higher than that in AIDS group (P < 0. 05). The expression of TLR8 was no singnificantly difference between SP group and HIV group or normal control group, so was it between HIV group or normal control group and AIDS group. Conclusion The expression of TLR7/8 in monocytes from HIV-1 infected patients significantly correlated with disease progression.